Radiopharm Theranostics ( ASX:RAD ) Full Year 2024 Results Key Financial Results Net loss: AU$47.9m (loss widened by...
Potential Radiopharm Theranostics Limited ( ASX:RAD ) shareholders may wish to note that the Non-Executive Director...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The